Form 144 notice for planned sale of 400 shares

A person associated with the issuer has filed a Form 144 to potentially sell 400 shares of common stock through J.P.

Rhea-AI Filing Summary

A person associated with the issuer has filed a Form 144 to potentially sell 400 shares of common stock through J.P. Morgan Securities LLC on or about 02/09/2026 on NASDAQ. The filing lists an aggregate market value of 314204 for these shares and notes that 103902660 shares of this class were outstanding. The 400 shares were originally acquired on 08/22/2013 from the issuer as compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the REGN Form 144 filing disclose about planned share sales?

The Form 144 filing discloses a planned sale of 400 common shares. These shares are to be sold through J.P. Morgan Securities LLC on or about February 9, 2026 on NASDAQ, with an aggregate market value listed as 314204.

How many REGN shares are covered and what is their aggregate market value?

The notice covers 400 shares of common stock with an aggregate market value of 314204. This value comes directly from the Form 144 table describing the number of units to be sold and their total market value at the time of the filing.

When were the REGN shares in this Form 144 originally acquired and how?

The 400 common shares were acquired on 08/22/2013 as compensation from the issuer. The filing states the nature of the acquisition transaction as “Compensation” and lists the issuer as the source of the shares.

What does the Form 144 say about REGN shares outstanding?

The filing reports 103902660 shares of the issuer’s common stock outstanding. This figure appears in the securities information table and serves as a baseline context for the planned sale of 400 shares.

Which broker is handling the planned REGN share sale in this Form 144?

The planned sale is to be handled by J.P. Morgan Securities LLC. The broker’s address is listed as 270 Park Avenue, 10th Floor, New York, NY 10017, and the transaction is noted as taking place on NASDAQ.

What representation does the seller make in the REGN Form 144 filing?

The seller represents that they do not know any undisclosed material adverse information about the issuer. By signing, they also acknowledge that intentional misstatements or omissions can constitute federal criminal violations under 18 U.S.C. 1001.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 05:02 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001187443
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Regeneron Pharmaceuticals, Inc.
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill River Road Tarrytown New York NEW YORK 10591
Phone	914-847-7000
Name of Person for Whose Account the Securities are To Be Sold	Arthur F. Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	400	314204	103902660	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/22/2013	Compensation	Issuer			400	08/22/2013	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Arthur F. Ryan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)